HC-1119

DRUG4 trials

Sponsors

Hinova Pharmaceuticals Inc., Hinova Pharmaceuticals USA, Inc., Applied Biology, Inc.

Conditions

COVID-19 Respiratory InfectionCastration-resistant Prostate CancerMCRPCMetastatic Castration Resistant Prostate CancerProstate Cancer Metastatic

Phase 1

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

CompletedNCT03774056

Hinova Pharmaceuticals Inc.Metastatic Castration Resistant Prostate Cancer

Start: 2017-02-10End: 2019-08-28Updated: 2020-11-03

Phase 3

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

TerminatedNCT03850795

Hinova Pharmaceuticals USA, Inc.Castration-resistant Prostate Cancer, Prostate Cancer Metastatic

Start: 2021-03-15End: 2024-06-28Updated: 2024-08-19

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

RecruitingNCT03851640

Hinova Pharmaceuticals Inc.MCRPC

Start: 2019-04-12End: 2025-09-30Target: 417Updated: 2025-03-12

HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

Applied Biology, Inc.COVID-19 Respiratory Infection

Start: 2022-04-15End: 2022-12-31Target: 602Updated: 2022-02-18

Related Papers

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.

2026-04-13

Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.

Journal of Clinical Oncology2023-06-013 citations

Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.

2021-07-0712 citations